NAPWA, TAEP to Urge Congress to Implement Healthcare Reform, End Federal Bans Targeting HIV-Positive Americans at AIDSWatch 2012
19 avr. 2012 08h00 HE
|
National Association of People with AIDS
WASHINGTON, DC--(Marketwire - Apr 19, 2012) - Today the National Association of People with AIDS (NAPWA) and the Treatment Access Expansion Project (TAEP) announces AIDSWatch 2012, the largest...
VIRxSYS Issued U.S. Patents for Its Lentiviral Vector and SMaRT RNA Platforms
15 nov. 2011 09h10 HE
|
VIRxSYS Corporation
GAITHERSBURG, MD--(Marketwire - Nov 15, 2011) - VIRxSYS Corporation, a Maryland-based biotechnology company, today announced that the United States Patent and Trademark Office has issued two...
New HIV Research Findings to Be Presented at NAPWA "Treatment Horizons: Pathways to a Functional Cure" Satellite Symposium, International AIDS Society, Rome
15 juil. 2011 07h30 HE
|
National Association of People with AIDS
SILVER SPRING, MD and ROME--(Marketwire - Jul 15, 2011) - HIV researchers working towards developing potential functional cures from three continents will present new data that collectively light a...
"Next Generation" HIV/AIDS Treatments Featured in NAPWA and The AIDS Institute's Community Forum at XVIII International AIDS Conference
22 juil. 2010 11h07 HE
|
National Association of People with AIDS
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - New data presented by researchers at the XVIII International AIDS Conference this week shows significant momentum for the emerging field of...
"Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies" to Be Showcased at NAPWA Sponsored Community Treatment Research Forum at XVIII World AIDS Conference
13 juil. 2010 13h45 HE
|
National Association of People with AIDS
SILVER SPRING, MD--(Marketwire - July 13, 2010) - The National Association of People with AIDS today announced that it is hosting a Community Treatment Research Forum, "Research Advances from...
GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, With the Greatest Effect in the Hardest-to-Treat Patients
19 avr. 2010 07h00 HE
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company's investigational Tarmogen® product for hepatitis C virus (HCV) infection,...
GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV
15 avr. 2010 13h00 HE
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen® product candidate, demonstrating...